The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment

Exclusion Criteria14

• Subjects with known hypersensitivity to any components of YUTIQ.
• Female subjects who are pregnant or breastfeeding.
• Has any acute or chronic medical disease or psychiatric condition that, in the opinion of the Investigator, would preclude participation in the study or put the subject at risk due to study treatment or procedures.
• History of anterior uveitis only (without associated uveitis that affected the posterior segment).
• Presence of a vitreous hemorrhage.
• Uveitis with infectious etiology.
• Intraocular inflammation associated with a condition other than non-infectious uveitis (e.g., intraocular lymphoma).
• Current infectious diseases of the cornea and conjunctiva, mycobacterial infections of the eye, or fungal diseases of ocular structures.
• Subjects with ACIOL (Anterior Chamber Intraocular Lens) or rupture of the posterior lens capsule.
• Diagnosis of any form of glaucoma or ocular hypertension at screening, unless the study eye is being treated with ≤2 intraocular pressure (IOP)-lowering medications and/or has been previously treated with an incisional surgical procedure resulting in stable IOP in the normal range (10 to 21 mmHg).
• Intraocular pressure \>21 mmHg or concurrent therapy at screening with \>2 IOP-lowering pharmacologic agents in the study eye.
• Any eye surgery within 12 weeks prior to Day 1 of the study.
• Subjects who are unable to attend scheduled follow-up visits throughout the 12-month study.
• Has a significant media opacity precluding evaluation of retina and vitreous in the study eye.